CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

Author： Bornhauser Martin   Jenke Andreas   Freiberg-Richter Jens   Radke Jörgen   Schuler Ulrich   Mohr Brigitte   Ehninger Gerhard   Schleyer Eberhard  

Publisher： Springer Publishing Company

ISSN： 0939-5555

Source： Annals of Hematology, Vol.83, Iss.6, 2004-06, pp. : 401-402

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia

By Gutierrez-Aguirre Cesar Homero   Garcia-Rodriguez Fernando   Ortiz-Galvez Victor Manuel   Cantu-Rodriguez Olga Graciela   Salazar-Riojas Rosario   Martinez-Gonzalez Odra Lizzette   Gonzalez-Llano Oscar   Jaime-Pérez Jose Carlos   Ortiz-Lopez Rocio   Flores-Jimenez Juan Antonio   Alatorre-Ricardo Julio   Mancias-Guerra Consuelo   Gomez-Almaguer David  

Hematology, Vol. 18, Iss. 4, 2013-07 ,pp. : 224-229

Maney Publishing

Access to resources Recommend Favorite

Bilateral Toxoplasma Retinochoroiditis in a Patient with Chronic Myeloid Leukemia Treated with Imatinib Mesylate

By Basu Soumyava   Das Taraprasad   Biswas Ghanshyam  

Ocular Immunology and Inflammation, Vol. 18, Iss. 1, 2010-01 ,pp. : 64-65

Informa Healthcare

Access to resources Recommend Favorite

Imatinib Mesylate in Chronic Myeloid Leukemia

By  

Current Stem Cell Research & Therapy, Vol. 2, Iss. 3, 2007-09 ,pp. : 249-251

Bentham Science Publishers

Access to resources Recommend Favorite

In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia

By La Rosee P.   Johnson K.   O'Dwyer M.E.   Druker B.J.  

Experimental Hematology, Vol. 30, Iss. 7, 2002-07 ,pp. : 729-737

Elsevier

Access to resources Recommend Favorite

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase

By Giles F.J.   Feldman E.J.   Roboz G.J.   Larson R.A.   Mamus S.W.   Cortes J.E.   Verstovsek S.   Faderl S.   Talpaz M.   Beran M.   Albitar M.   O'Brien S.M.   Kantarjian H.M.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1091-1096

Elsevier

Access to resources Recommend Favorite